Takeda (TAK) CMO sells 14,006 ADSs in mandatory tax-cover share sale

Rhea-AI Filing Summary

Takeda Pharmaceutical Co. Ltd. reports that Chief Medical Officer Farajallah Awny Samaan Botros sold 14,006 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction represents a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, Botros directly holds 116,177 American Depositary Shares.

Insider Trade Summary

Net Seller: 14,006 shares

Net Sell 1 txn

Insider Farajallah Awny Samaan Botros

Role Chief Medical Officer

Sold 14,006 shs ($240K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	14,006	$17.10	$240K

Holdings After Transaction: American Depositary Shares — 116,177 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 14,006 American Depositary Shares Sale price: $17.10 per share Shares held after transaction: 116,177 American Depositary Shares +1 more

4 metrics

Shares sold 14,006 American Depositary Shares Non-derivative sale on 2026-08-10 to cover taxes on vesting awards

Sale price $17.10 per share Weighted average sale price for American Depositary Shares sold

Shares held after transaction 116,177 American Depositary Shares Direct holdings of Chief Medical Officer after the sale

Net shares sold 14,006 shares Net-sell direction based on transaction summary

Key Terms

American Depositary Shares, mandatory sale to cover taxes, weighted average price

3 terms

American Depositary Shares financial

"Represents a sale of American Depositary Shares by the reporting person"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transaction did TAK report for Chief Medical Officer Farajallah Botros?

Takeda (TAK) reported that Chief Medical Officer Farajallah Awny Samaan Botros sold 14,006 American Depositary Shares on 2026-08-10 as a mandatory sale to cover taxes related to vesting equity awards.

At what price were the 14,006 Takeda (TAK) shares sold by the CMO?

The 14,006 American Depositary Shares were sold at a weighted average price of $17.10 per share. The filing notes this as a weighted average and offers to provide full breakdowns of shares sold at each price upon request.

Why did Takeda (TAK) Chief Medical Officer sell 14,006 shares?

The sale of 14,006 American Depositary Shares by Takeda’s Chief Medical Officer was described as a mandatory sale to cover taxes associated with the vesting of equity awards held by the reporting person.

How many Takeda (TAK) shares does the CMO hold after this Form 4 transaction?

After the reported transaction, Chief Medical Officer Farajallah Awny Samaan Botros directly holds 116,177 American Depositary Shares of Takeda Pharmaceutical Co. Ltd., according to the post-transaction holdings figure in the Form 4.

Was the Takeda (TAK) CMO’s August 2026 share sale under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the footnotes describe the sale as a mandatory tax-cover transaction related to vesting equity awards, rather than a discretionary trading-plan sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 09:54 PM Accepted by SEC EDGAR 08/12/2026 - 09:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farajallah Awny Samaan Botros

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		14,006	D	$17.1(2)	116,177	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Awny S. Farajallah	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)